Skip to main content

Advertisement

SpringerLink
Log in

Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods?

  • Controversies—Against
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.

References

  1. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002; 43:693–713.

    Google Scholar 

  2. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol 2001; 39:195–201.

    Google Scholar 

  3. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453–2463.

    Google Scholar 

  4. Goodwin DA. Pharmacokinetics and antibodies. J Nucl Med 1987; 28:1358–1362.

    Google Scholar 

  5. Goodwin DA. New methods for localizing infection: a role for avidin-biotin? J Nucl Med 1992; 33:1816–1818.

    Google Scholar 

  6. Goodwin DA. Tumor pretargeting: almost the bottom line. J Nucl Med 1995; 36:876–879.

    Google Scholar 

  7. Lovqvist A, Divgi C. Bullets to magic bullets and miles to go before we sleep. J Nucl Med 1998; 39:1776–1777.

    Google Scholar 

  8. Goodwin DA, Meares CF. Pretargeted peptide imaging and therapy. Cance Biotherapy Radiopharmaceuticals 1999; 14:145–152.

    Google Scholar 

  9. Le Doussal JM, Barbet J, Delaage M. Bispecific-antibody-mediated targeting of radiolabeled bivalent haptens: theoretical, experimental, and clinical results. Int J Cancer (Suppl) 1992; 7:58–62.

    Google Scholar 

  10. Chatal, JF, Faivre-Chauvet A, Bardies M, Peltier P, Gautherot E, Barbet J. Bifunctional antibodies for radioimmunotherapy. Hybridoma 1995; 14:125–128.

    Google Scholar 

  11. Rosebrough SF. Two-step immunological approaches for imaging and therapy. Q J Nucl Med 1996; 40:234–251.

    Google Scholar 

  12. Goodwin DA, Meares CF. Pretargeting: general principles. Cancer (Suppl) 1997; 80:2675–2680.

    Google Scholar 

  13. Fritzberg AR. Antibody pretargeted radiotherapy: a new approach and a second chance. J Nucl Med 1998; 39:20N.

    Google Scholar 

  14. Barbet J, Kraeber-Bodéré F, Vuillez, JP, Gautherot E, Rouvier E, Chatal JF. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm 1999; 14:153–166.

    Google Scholar 

  15. Gruaz-Guyon A, Janevik-Ivanovska E, Raguin O, De Labriolle-Vaylet C, Barbet J. Radiolabeled bivalent haptens for tumor immunodetection and radioimmunotherapy. Q J Nucl Med 2001; 45:201–206.

    Google Scholar 

  16. Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W, Hansen HJ, Chatal JF, Barbet J, Goldenberg DM. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol Cancer Ther 2002; 1:553–563.

    Google Scholar 

  17. Hnatowich DJ, Virzi F, Ruschowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med 1987; 28:1294–1302.

    Google Scholar 

  18. Paganelli G, Riva P, Deleide G, Clivio A, Chiolerio F, Scassellati GA, Malcovati M, Siccardi AG. In vivo labeling of biotinylated monoclonal antibodies by radioactive avidin: a strategy to increase tumor radiolocalization. Int J Cancer (Suppl) 1988; 2:121–125.

    Google Scholar 

  19. Axworthy DM, Reno JM, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, Su F, Hobson LJ, Beaumier PL, Fritzberg AR. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A 2000; 97:1802–1807.

    Google Scholar 

  20. Goodwin DA, Meares CF, McCall MJ, McTigue M, Chaovapong W. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med 1998; 29:226–234.

    Google Scholar 

  21. Goodwin DA, Meares CF, McTigue M, Chaovapong W, Diamanti CI, Ransone CH, McCall MJ. Pretargeted immunoscintigraphy: effect of hapten valency on murine tumor uptake. J Nucl Med 1992; 33:2006–2013.

    Google Scholar 

  22. Rusckowski M, Fritz B, Hnatowich DJ. Localization of infection using straptavidin and biotin: an alternative to nonspecific polyclonal immunoglobulin. J Nucl Med 1992; 33:1810–1815.

    Google Scholar 

  23. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989; 30:1358–1366.

    Google Scholar 

  24. Stickney DR, Slater JB, Kirk GA, Ahlem C, Chang CH, Frincke JM. Bifunctional antibody: ZCE/CHA111Indium BLEDTA-IV clinical imaging in colorectal carcinoma. Antibody Immunoconjug Radiopharm 1989; 2:1–13.

    Google Scholar 

  25. Hosono M, Hosono MN, Kraeber-Bodéré F, Devys A, Thédrez P, Faivre-Chauvet A, Gautherot E, Barbet J, Chatal JF. Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NACM/antihistamine bispecific antibody and radioiodinated bivalent hapten. J Nucl Med 1999; 40:1216–1221.

    Google Scholar 

  26. Sharkey RM, Rossi E, Karacay H, McBride W, Chang K, Zeng L, Qu T, Griffiths G, Hansen HJ, Goldenberg DM. A novel recombinant bispecific antibody pretargeting system for cancer radioimmunotherapy [abstract]. Clin Cancer Res (Suppl) 2002; 7:3786s.

    Google Scholar 

  27. Kalofonos HP, Rusckowski M, Siebecker DA, Sivolapenko GB, Snook D, Lavender JP, Epenetos AA, Hnatowich DJ. Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication. J Nucl Med 1990; 31:1791–1796.

    Google Scholar 

  28. Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, Fiorenza M, Gatti M, Caliceti P, Paganelli G. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: A pilot study. Br J Cancer 2002; 86:207–212.

    Google Scholar 

  29. Saga T, Weinstein J N, Jeong JM, Heya T, Le JT, Le N, Paik CH, Sung C, Neumann R. Two-step targeting of experimental lung metastases with biotinylated sntibody and radiolabeled streptavidin. Cancer Res 1994; 54:2160–2165.

    Google Scholar 

  30. Wilbur DS, Hamlin DK, Vessella RL, Stray JE, Buhler KR, Stayton PS, Klumb LA, Pathare PM, Weerawarna SA. Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab' colocalization with recombinant streptavidin and avidin. Bioconjugate Chem 1996; 7:689–702.

    Google Scholar 

  31. Kuijpers WHA, Bos ES, Kaspersen FM, Veeneman GH, van Boeckel CAA. Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides: a novel approach for two-step radioimmunotherapy of cancer. Bioconjugate Chem 1993; 4:94–102.

    Google Scholar 

  32. Rusckowski M, Qu T, Chang F, Hnatowich DJ. Pretargeting using peptide nucleic acid. Cancer (Suppl) 1997; 80:2699–2705.

    Google Scholar 

  33. Bagshawe KD, Sharma SK, Burke PJ, Melton RG, Knox RJ. Developments with targeted enzymes in cancer therapy. Curr Opin Immunol 1999; 11:579–583.

    Google Scholar 

  34. Gautherot E, Rouvier E, Daniel L, Loucif E, Bouhou J, Manetti C, Martin M, LeDoussal J-M, Barbet J. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and131I-labeled bivalent hapten. J Nucl Med 2000; 41:480–487.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Molecular Medicine and Immunology, Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109-0023, USA

    David M. Goldenberg, Robert M. Sharkey & Habibe Karacay

  2. Immunomedics Inc., , 300 American Road, Morris Plains, NJ 07950, USA

    David M. Goldenberg, William McBride & Hans J. Hansen

  3. IBC Pharmaceuticals Inc., , 300 American Road, Morris Plains, NJ 07950, USA

    David M. Goldenberg, Chien-Hsing Chang & Edmund A. Rossi

  4. Centre René Gauducheau and INSERM U463, , Nantes, France

    Jean-Francois Chatal & Jacques Barbet

Authors
  1. David M. Goldenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chien-Hsing Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert M. Sharkey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Edmund A. Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Habibe Karacay
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. William McBride
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hans J. Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jean-Francois Chatal
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jacques Barbet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David M. Goldenberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goldenberg, D.M., Chang, CH., Sharkey, R.M. et al. Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods?. Eur J Nucl Med Mol Imaging 30, 777–780 (2003). https://doi.org/10.1007/s00259-002-1089-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-002-1089-6

Keywords

Search

Navigation